Skip to main content

Advertisement

Table 1 Baseline characteristics and Jadad score of included study

From: Dolutegravir(DTG, S/GSK1349572) combined with other ARTs is superior to RAL- or EFV-based regimens for treatment of HIV-1 infection: a meta-analysis of randomized controlled trials

Authors publish time Study phase Location Sample characteristics Trial quality
Age (years) Sex: male Race Blinding described, appropriate Randomization described, appropriate Losses to follow-up described Jadad score
Jan van Lunzen et al. 2012. [20] Phase IIb France, Germany, Italy, Russia, Spain, the USA ≥18 DTG: 10 mg (Mean = 32) 25 mg( Mean = 38) 50 mg (Mean = 37) EFV: 600 mg (Mean = 40) DTG: 10 mg (42/53) 25 mg (46/51) 50 mg (45/51) EFV: 600 mg (44/50) White: (164/205, 80 %) Black: (25/205, 12 %) Other: (16/205, 8 %) Yes, yes Yes, yes Yes 5
S. Walmsley et al. 2012. [22] Phase III Toronto, Canada, Belgium, Spain, Italy DTG: 50 mg (Mean = 36) EFV: 50 mg (Mean = 35) DTG: 50 mg (378/414) EFV: 400 mg (63/419) White: (566/833, 68 %) Black: (200/833, 24 %) Other: (67/833, 6 %) Yes, yes Yes, yes Yes 5
Pedro Cahn et al. 2013. [23] Phase III (156 centers) Australia, Canada, Europe, Latin, America, Taiwan, South Africa, the USA ≥18 DTG: 50 mg (Mean = 42) RAL: 400 mg (Mean = 43) DTG: 50 mg (247/354) RAL: 400 mg (238/361) White: (347/715, 49 %) Black: (303/715, 42 %) Other: (65/715, 9 %) Yes, yes Yes, yes Yes 5
Francois Raffi et al. 2013. [21] Phase III (100 sites) Canada, USA, Australia, Europe ≥18 DTG: 50 mg (Mean = 37) RAL: 400 mg (Mean = 35) DTG: 50 mg (348/411) RAL: 400 mg (355/411) White: (698/822, 85 %) Black: (88/822, 11 %) Other: (36/822, 4 %) Yes, yes Yes, yes Yes 5
  1. DTG dolutegravir, S/GSK1349572; RAL raltegravir; EFV efavirenz